← Back to Clinical Trials
Recruiting NCT06732869

NCT06732869 Effectiveness of a Physical ACtivity Coaching Intervention Using E-Health for COPD Patients in Pulmonary Rehabilitation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06732869
Status Recruiting
Phase
Sponsor Instituto Politécnico de Leiria
Condition COPD
Study Type INTERVENTIONAL
Enrollment 57 participants
Start Date 2024-12-02
Primary Completion 2025-06

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
eHealth physical activity coaching interventionpulmonary rehabilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 57 participants in total. It began in 2024-12-02 with a primary completion date of 2025-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this randomized controlled trial is to evaluate the efficacy of a physical activity coaching intervention - delivered through an eHealth platform both during and after pulmonary rehabilitation - to enhance physical activity levels and health-related outcomes in patients with Chronic Obstructive Pulmonary Disease (COPD). All participants will attend the pulmonary rehabilitation program for 2 months; the experimental group will receive a physical activity coaching intervention at the end of the 1st month of the rehabilitation program, which will continue for 6 months following the completion of the program. Assessments will be conducted at the beginning, midway, and at the end of the coaching program, as well as 3 months and 6 months after its conclusion.

Eligibility Criteria

Inclusion criteria: * age \> 40 years old * diagnosis of COPD according to GOLD criteria, clinically stable (i.e., with no exacerbations in the previous month) * being enrolled in a pulmonary rehabilitation program * having a smartphone with access to the internet * being able to understand and provide informed consent. Exclusion criteria: * simultaneous participation in another behavioural modification program * having any clinical condition that precludes participation in a PA intervention (e.g., severe musculoskeletal or neurological disorders and unstable cardiovascular disease) * another primary respiratory disease * history of recent neoplasia (including last treatment) in the previous year.

Contact & Investigator

Central Contact

Sofia Flora, PT, MSc

✉ sofia.flora@ipleiria.pt

📞 +351 917257840

Principal Investigator

Sofia Flora, PT, MSc

PRINCIPAL INVESTIGATOR

Center for Innovative Care and Health Technology, Polytechnic of Leiria

Frequently Asked Questions

Who can join the NCT06732869 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06732869 currently recruiting?

Yes, NCT06732869 is actively recruiting participants. Contact the research team at sofia.flora@ipleiria.pt for enrollment information.

Where is the NCT06732869 trial being conducted?

This trial is being conducted at Leiria, Portugal.

Who is sponsoring the NCT06732869 clinical trial?

NCT06732869 is sponsored by Instituto Politécnico de Leiria. The principal investigator is Sofia Flora, PT, MSc at Center for Innovative Care and Health Technology, Polytechnic of Leiria. The trial plans to enroll 57 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology